Related resources and publications
Targeting the human CD47/SIRPα axis
Humanized ICP mouse and cell lines
Front Immunol
PLoS One
Immunology
The MC38-hPD-L1-hHER2-LZ clonal cell line expresses high levels of human PD-L1 and human HER2.
The MC38 cell line was derived from C57BL/6 murine colon adenocarcinoma cells. They form solid tumors upon subcutaneous injection in immunocompetent mice.
We generated a MC38-hPD-L1-hHER2-LZ clonal cell line expressing high levels of human PD-L1 (CD274 NCBI GeneID: 29126) and human HER2 (ERBB2 NCBI GeneID: 2064), and an optimized dual fusion reporter luciferase-ZsGreen (LZ). These cells are invalidated for murine Pd-l1 (Cd274, NCBI Gene ID: 60533). MC38-hPD-L1-hHER2-LZ cells form solid tumors in vivo. Isogenic wild-type (WT) and luciferase-ZsGreen (LZ) control clones are available.
Expression analysis by flow cytometry. Human PD-L1 and HER2 expression assessed in MC38 parental cell line (top left), human control cell line – RKO (bottom left) and BT474 (bottom right), and MC38-hPD-L1-hHER2-LZ cell line (top right). Human HER2 was detected using Trastuzumab antibody.
C57/Bl6 mice were injected (s.c.) with 2x106 MC38-hPD-L1-LZ cells (left) or MC38-hPD-L1-hHER2-LZ cells (right). Tumor growth was measured every 2 to 3 days. Tumor size (mm3) = (width² x length)/2.
Targeting the human CD47/SIRPα axis
Humanized ICP mouse and cell lines
Front Immunol
PLoS One
Immunology
Let us know how we can help
Physiological relevance
Comprehensive and reliable validation data
Over 600 scientific articles based on our models
In-depth expertise in preclinical science, physiology, and model development
Unique R&D platform located in France
Tailor-made approach to your needs
Strong emphasis on customer satisfaction
Long-standing partnerships with 17 of the top 20 pharma companies
Co-development of innovative models for next-generation drugs
Guaranteed FTO/freedom to operate